Characteristics of gastric cancer in peptic ulcer patients with Helicobacter pylori infection

World J Gastroenterol. 2015 Apr 28;21(16):4954-60. doi: 10.3748/wjg.v21.i16.4954.

Abstract

Aim: To evaluate the incidence and clinical characteristics of gastric cancer (GC) in peptic ulcer patients with Helicobacter pylori (H. pylori) infection.

Methods: Between January 2003 and December 2013, the medical records of patients diagnosed with GC were retrospectively reviewed. Those with previous gastric ulcer (GU) and H. pylori infection were assigned to the HpGU-GC group (n = 86) and those with previous duodenal ulcer (DU) disease and H. pylori infection were assigned to the HpDU-GC group (n = 35). The incidence rates of GC in the HpGU-GC and HpDU-GC groups were analyzed. Data on demographics (age, gender, peptic ulcer complications and cancer treatment), GC clinical characteristics [location, pathological diagnosis, differentiation, T stage, Lauren's classification, atrophy of surrounding mucosa and intestinal metaplasia (IM)], outcome of eradication therapy for H. pylori infection, esophagogastroduodenoscopy number and the duration until GC onset were reviewed. Univariate and multivariate analyses were performed to identify factors influencing GC development. The relative risk of GC was evaluated using a Cox proportional hazards model.

Results: The incidence rates of GC were 3.60% (86/2387) in the HpGU-GC group and 1.66% (35/2098) in the HpDU-GC group. The annual incidence was 0.41% in the HpGU-GC group and 0.11% in the HpDU-GC group. The rates of moderate-to-severe atrophy of the surrounding mucosa and IM were higher in the HpGU-GC group than in the HpDU-GC group (86% vs 34.3%, respectively, and 61.6% vs 14.3%, respectively, P < 0.05). In the univariate analysis, atrophy of surrounding mucosa, IM and eradication therapy for H. pylori infection were significantly associated with the development of GC (P < 0.05). There was no significant difference in the prognosis of GC patients between the HpGU-GC and HpDU-GC groups (P = 0.347). The relative risk of GC development in the HpGU-GC group compared to that of the HpDU-GC group, after correction for age and gender, was 1.71 (95%CI: 1.09-2.70; P = 0.02).

Conclusion: GU patients with H. pylori infection had higher GC incidence rates and relative risks. Atrophy of surrounding mucosa, IM and eradication therapy were associated with GC.

Keywords: Duodenal ulcer; Eradication therapy; Gastric cancer; Gastric ulcer; Helicobacter pylori.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Ulcer Agents / therapeutic use
  • Chi-Square Distribution
  • Duodenal Ulcer / diagnosis
  • Duodenal Ulcer / drug therapy
  • Duodenal Ulcer / epidemiology
  • Duodenal Ulcer / microbiology*
  • Female
  • Helicobacter Infections / diagnosis
  • Helicobacter Infections / drug therapy
  • Helicobacter Infections / epidemiology
  • Helicobacter Infections / microbiology*
  • Helicobacter pylori / isolation & purification*
  • Humans
  • Incidence
  • Male
  • Medical Records
  • Middle Aged
  • Multivariate Analysis
  • Prognosis
  • Proportional Hazards Models
  • Proton Pump Inhibitors / therapeutic use
  • Republic of Korea / epidemiology
  • Retrospective Studies
  • Risk Factors
  • Stomach / microbiology*
  • Stomach / pathology
  • Stomach Neoplasms / epidemiology
  • Stomach Neoplasms / microbiology*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / therapy
  • Stomach Ulcer / diagnosis
  • Stomach Ulcer / drug therapy
  • Stomach Ulcer / epidemiology
  • Stomach Ulcer / microbiology*
  • Time Factors

Substances

  • Anti-Bacterial Agents
  • Anti-Ulcer Agents
  • Proton Pump Inhibitors